Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.
Last trade$2.90
Day change+$0.06 (+2.11%)
Day range$2.76 – $2.96
Volume309,839
Market cap$135M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$134.84M
Price / earnings
—
Price / book
0.61×
Price / sales
0.91×
EV / sales
0.67×
EV / EBITDA
-1.5×
Profitability
Earnings per share
-$2.34
Return on assets
-37.01%
Return on equity
-50.69%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3.09×
Quick ratio
2.22×
Cash ratio
0.7×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$56.03M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for QTRX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$34.97M
$32.91M
$36.42M
$43.86M
$40.23M
$24.48M
$30.33M
$35.16M
Cost of revenue
$21.47M
$20.23M
$20.85M
$23.82M
$24.33M
$14.48M
$15.5M
$12.99M
Gross profit
$13.5M
$12.67M
$15.57M
$20.04M
$15.9M
$10M
$14.84M
$22.17M
Selling, general and administrative
$28.45M
$27.35M
$29.77M
$35.14M
$38.04M
$30.35M
$31.17M
$28.59M
Research and development
$7.37M
$7.82M
$7.32M
$8.8M
$8.01M
$9.08M
$10.04M
$8.07M
Total operating expenses
$36M
$62.11M
$55.43M
$44.79M
$53.23M
$47.1M
$41.58M
$36.94M
Operating income
-$22.5M
-$49.43M
-$39.86M
-$24.75M
-$37.33M
-$37.1M
-$26.75M
-$14.77M
Interest expense
$0
$0
$0
$1.16M
$0
$0
$0
$3.49M
Income before taxes
-$21.3M
-$48.99M
-$17.55M
-$22.77M
-$36M
-$30.09M
-$23.42M
-$11.64M
Income taxes
$288K
-$54K
-$7K
$345K
-$2.48M
-$73K
-$2.91M
-$8K
Net income
-$21.59M
-$48.93M
-$17.54M
-$23.12M
-$33.52M
-$30.01M
-$20.5M
-$11.63M
Net income attributable to common shareholders
-$21.59M
-$48.93M
-$17.54M
-$23.12M
-$33.52M
-$30.01M
-$20.5M
-$11.63M
EBITDA
-$15.89M
-$16.36M
-$15.92M
-$17.64M
-$24.72M
-$27.43M
-$24.18M
-$13.05M
Basic earnings per share
-$0.46
-$1.04
-$0.37
-$0.49
-$0.73
-$0.77
-$0.53
-$0.30
Diluted earnings per share
-$0.46
-$1.04
-$0.37
-$0.49
-$0.73
-$0.77
-$0.53
-$0.30
Recent news
Company coverage with links to the original publishers.
The global Alzheimer's disease biomarker market is projected to grow from USD 2.2 billion in 2025 to USD 4.7 billion by 2034, driven by rising disease prevalence, aging populations, and advancements in blood-based biomarkers like phosphorylated tau and amyloid-beta assays. North America leads the market with 41% share, while Asia-Pacific is the fastest-growing region. Recent FDA clearances and expanded laboratory testing availability are accelerating market adoption.
The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with 34% market share, while Asia Pacific is the fastest-growing region at 15.5% CAGR. Consumables dominate with 68% market share, and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, and laboratory automation.
The global blood-based biomarkers market is projected to grow from USD 8.5 billion in 2025 to USD 18.5 billion by 2034, driven by increasing demand for non-invasive diagnostics, rising chronic disease prevalence, and advances in genomics and liquid biopsy technologies. North America leads with 44% market share, while Asia-Pacific shows fastest growth. Key players include Roche, Abbott, Siemens Healthineers, and Thermo Fisher Scientific.
The article discusses the growing cancer treatment market, with a focus on companies like Oncolytics Biotech, Akoya Biosciences, Quanterix, TScan Therapeutics, and Arcellx. It highlights new data and collaborations that signal a turning point for precision-driven cancer biotechs.
Monteverde & Associates PC, a class action law firm, is investigating several proposed mergers, including Akoya Biosciences' merger with Quanterix, Welsbach Technology Metals Acquisition's merger with Evolution Metals LLC, and Playa Hotels & Resorts' merger with Hyatt Hotels Corporation.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.